!

COVID-19 Response 

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Dan L Duncan Comprehensive Cancer Center

Children’s Access to Regenerative Medicine in Texas

Master
Content

CARMIT (Children’s Access to Regenerative Medicine in Texas) is a core service of the Cancer Prevention and Research Institute of Texas (CPRIT). Its aim is to provide cellular therapy products and viral vectors to treat pediatric cancer patients at Texas Academic Institutions. Manufacturing of these products must be performed under FDA regulations and Good Manufacturing Practices (GMP). The GMP facility at Baylor College of Medicine Center for Cell and Gene Therapy (CAGT) is one of the largest and most modern academic centers in the country. The staff is highly experienced in manufacturing a very wide variety of cellular therapy products and viral vectors used for genetic modification of cells. CARMIT will cover some of the cost of making and testing your product and providing it for your clinical trial.

To be eligible to apply for CARMIT support you must be a physician scientist at a Texas Academic Center. Initial applications are short and are reviewed by a CAGT Internal Review Panel for scientific content and manufacturing feasibility. Successful applicants are then requested to submit a slightly longer application form describing the product to be made and the pediatric clinical protocol in which it is to be used, IND status etc. This is reviewed by an External Advisory Board composed of cellular therapy experts at renowned institutions. To apply, please complete the initial application located below, and submit it to Dr. Adrian Gee at apgee@txch.org.

Successful applicants will work with a CARMIT representative to develop a manufacturing timeline and budget.

Applications

Primary Location

  • Feigin Center at Texas Children's Hospital
  • 16th Floor Offices and GMP facilities
  • 17th Floor Translational Research
  • 17th Floor Protocol & Regulatory Affairs